Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Mar 15;193(6):792-5.
doi: 10.1086/500469. Epub 2006 Feb 9.

Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome

Wei Liu  1 , Arnaud Fontanet, Pan-He Zhang, Lin Zhan, Zhong-Tao Xin, Laurence Baril, Fang Tang, Hui Lv, Wu-Chun Cao
Affiliations

Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome

Wei Liu et al. J Infect Dis. .

Abstract

In a cohort study of 56 convalescent patients with severe acute respiratory syndrome (SARS), titers of immunoglobulin G (IgG) antibodies and neutralizing antibodies (NAbs) against SARS-associated coronavirus were assessed at regular intervals (at 1, 4, 7, 10, 16, and 24 months after the onset of disease) by use of enzyme-linked immunosorbent assay and neutralization assay. IgG antibody and NAb titers were highly correlated, peaking at month 4 after the onset of disease and decreasing thereafter. IgG antibodies remained detectable in all patients until month 16, and they became undetectable in 11.8% of patients at month 24. The finding that NAbs remained detectable throughout follow-up is reassuring in terms of protection provided against reinfection; however, NAb titers decreased markedly after month 16.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kinetics of IgG antibody titers, by month after the onset of disease symptoms, for 56 patients with severe acute respiratory syndrome in Beijing, People’s Republic of China. N no. of study participants tested at each visit
Figure 2
Figure 2
Kinetics of neutralizing antibody (NAb) titers, by month after the onset of disease symptoms, for 56 patients with severe acute respiratory syndrome in Beijing, People’s Republic of China. N no. of participants tested at each visit
See this image and copyright information in PMC

References

    1. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348:1967–76. - PubMed
    1. World Health Organization (WHO) Investigation into China’s recent SARS outbreak yields important lessons for global public health. WHO Western Pacific Region. 2004 Available at: http://www.wpro.who.int/sars/docs/update/update_07022004.asp. Accessed 2 July 2005.
    1. Song HD, Tu CC, Zhang GW, et al. Cross‐host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc Natl Acad Sci USA. 2005;102:2430–5. - PMC - PubMed
    1. Chen X, Zhou B, Li M, et al. Serology of severe acute respiratory syndrome: implications for surveillance and outcome. J Infect Dis. 2004;189:1158–63. - PMC - PubMed
    1. Nie Y, Wang G, Shi X, et al. Neutralizing antibodies in patients with severe acute respiratory syndrome–associated coronavirus infection. J Infect Dis. 2004;190:1119–26. - PMC - PubMed

Publication types

MeSH terms